Jazz Pharmaceuticals plc (JAZZ) Stock

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc is led by CEO Renee D. Gala, employs 2,890 people, headquartered in Dublin, IE, publicly traded since 2007.

Jazz Pharmaceuticals plc (JAZZ) stock trades at $258.38 with a market capitalization of $16.23B. The stock is valued at a price-to-earnings (P/E) ratio of 2071.27, price-to-book of 3.24, price-to-sales of 3.23. Over the past 52 weeks the stock has ranged between $105.00 and $258.38, and currently trades at its 52-week high.

On profitability, Jazz Pharmaceuticals plc generates a return on equity (ROE) of 0.68%, return on capital employed of 17.51%, an operating margin of 11.13%, a net profit margin of 0.66%.

In its most recent fiscal year, Jazz Pharmaceuticals plc reported annual revenue of $4.3B, net profit of $-356.0M, revenue has compounded at 12.5% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 1.20, a current ratio of 1.86, total assets of $11.7B, $1.4B in cash and equivalents.

JAZZ has an average daily trading volume of 867,314 shares, a beta of 0.33 (less volatile than the overall market).

Official website: www.jazzpharma.com